癌症
癌细胞
抗药性
溶酶体
药品
癌症研究
药理学
生物
细胞生物学
酶
生物化学
遗传学
微生物学
作者
Ekta Shirbhate,Vaibhav Singh,Aditya Mishra,Varsha Jahoriya,Ravichandran Veerasamy,Amit K. Tiwari,Harish Rajak
出处
期刊:Mini-reviews in Medicinal Chemistry
[Bentham Science]
日期:2024-02-09
卷期号:24
标识
DOI:10.2174/0113895575287242240129120002
摘要
Abstract: Chemotherapy is still the major method of treatment for many types of cancer. Curative cancer therapy is hampered significantly by medication resistance. Acidic organelles like lysosomes serve as protagonists in cellular digestion. Lysosomes, however, are gaining popularity due to their speeding involvement in cancer progression and resistance. For instance, weak chemotherapeutic drugs of basic nature permeate through the lysosomal membrane and are retained in lysosomes in their cationic state, while extracellular release of lysosomal enzymes induces cancer, cytosolic escape of lysosomal hydrolases causes apoptosis, and so on. Drug availability at the sites of action is decreased due to lysosomal drug sequestration, which also enhances cancer resistance. This review looks at lysosomal drug sequestration mechanisms and how they affect cancer treatment resistance. Using lysosomes as subcellular targets to combat drug resistance and reverse drug sequestration is another method for overcoming drug resistance that is covered in this article. The present review has identified lysosomal drug sequestration as one of the reasons behind chemoresistance. The article delves deeper into specific aspects of lysosomal sequestration, providing nuanced insights, critical evaluations, or novel interpretations of different approaches that target lysosomes to defect cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI